Key Takeaways
- •There is no single Deadpool formula. At least three distinct compositions are sold under the name, and vendor pages rarely acknowledge that competing versions exist. Read the component list, not the nickname.
- •The name is marketing lineage, not chemistry. It descends from the "Wolverine stack" (BPC-157 plus TB-500), a nickname that started on bodybuilding forums. Deadpool is Wolverine plus one or two more compounds.
- •A large number of Cartalax listings print the wrong sequence. Cartalax is the tripeptide Ala-Glu-Asp (AED). Ala-Glu-Asp-Leu (AEDL) is Bronchogen, the bronchial peptide in the same Khavinson series. Listings that describe Cartalax as AEDL are describing a different compound.
- •Zero published studies evaluate any Deadpool formulation as a formulation. Every claim made for the blend is extrapolated from single-compound literature, and the single-compound literature is itself thin in humans.
- •A blend certificate cannot report purity the way a single-peptide certificate can. With four peptides in one vial, the largest chromatographic peak is not the product, it is a quarter of the product, and the other peaks are not impurities.
- •The fixed ratio is the trade. Components in one vial cannot be varied independently, and BPC-157 has an elimination half-life measured in minutes while the blend is sold as a single unit.
"Deadpool blend" is a nickname, not a formula. It is the single most important thing to understand about it, and almost no listing says so.
Search the term and you will find vials sold under that name containing three peptides, and other vials sold under the same name containing four. You will find one that is BPC-157 plus TB-500 plus Cartalax. You will find another that is BPC-157 plus TB-500 plus KPV. You will find a third that is BPC-157 plus TB-500 plus KPV plus GHK-Cu, which is more commonly sold as KLOW. The totals range from 20mg to 80mg per vial, the splits range from even thirds to a 5:1:1:1 ratio, and the only thing every version shares is two peptides and a Marvel character.
This page is a reference for laboratory and in-vitro research procurement. It explains what each formulation actually contains, what the published literature does and does not support for each component, why the sequence printed on many Cartalax listings belongs to a different peptide entirely, and why a multi-peptide vial is analytically harder to verify than the sum of its parts. There is no dosing, administration, protocol, or human-use guidance anywhere in it, and none should be inferred.
The Short Answer
A Deadpool blend is a single lyophilised vial containing several tissue-repair-associated research peptides, sold under a comic-book nickname rather than a compositional name. The two most common versions are:
| Version | Components | Typical vial | Also sold as |
|---|---|---|---|
| Cartalax version | BPC-157, TB-500, Cartalax | 20mg (5/5/10) or 30mg (10/10/10) | Deadpool Blend, BPC-157/TB4/Cartalax |
| KPV version | BPC-157, TB-500, KPV | 20mg (5/10/5) | Deadpool Stack |
| Four-peptide version | BPC-157, TB-500, KPV, GHK-Cu | 80mg (10/10/10/50) | KLOW, KLOW-80, Deadpool Stack |
One name, three vials. The container is identical in every case and the contents are not. In the four-peptide version the single largest component is 50mg of an 80mg vial.
Vendor aggregators list the Cartalax version under at least six different names, including "DEADPOOL (BPC-157 / TB500 / Cartalax)", "Deadpool Blend (BPC-157/TB4/Cartalax)", "Cartalax / TB4 / BPC" and "CARTALAX/BPC-157/TB-500". The four-peptide version is more often catalogued as KLOW, a mnemonic built from the leading letters of its components rather than an acronym for anything.
That naming sprawl is the practical problem. Two researchers comparing notes on "the Deadpool blend" may be describing vials that share only two of their three or four components, at ratios that differ by a factor of five.
Where the Name Comes From
The lineage starts with the Wolverine stack. Somebody on a bodybuilding forum noticed that BPC-157 and TB-500 were both being discussed for tissue repair, paired them, and reached for the most obvious pop-culture shorthand available: the X-Men character whose defining trait is regenerating whatever gets damaged. Search interest in that term grew from roughly 550 US searches a month in August 2023 to roughly 8,657 in August 2026.
Deadpool followed the same logic. In the source material the character's healing factor is derived from Wolverine's and is usually written as the more extreme version of it, so the name was available for whatever came after the two-peptide stack. Vendors applied it to their three- and four-component vials independently, which is exactly why the compositions never converged.
Neither name carries any information about ratio, purity, salt form, or evidence. They are product names in a market where a product name is often the only differentiator available.
The Components, One at a Time
Before the detail, the five compounds that appear in one version or another, at a glance:
| Compound | What it is | Length | Approx. MW | Strongest evidence | Appears in |
|---|---|---|---|---|---|
| BPC-157 | Synthetic gastric-juice-derived pentadecapeptide | 15 residues | 1419 Da | Rodent tissue repair models; three small human reports | All versions |
| TB-500 | Thymosin beta-4, or its Ac-LKKTETQ 17-23 fragment | 43 or 7 residues | ~4900 Da or ~890 Da | Phase 3 ophthalmic trials of the full protein, results split | All versions |
| KPV | C-terminal fragment of alpha-MSH | 3 residues | ~342 Da | Mechanistic cell work and rodent colitis models | KPV and four-peptide versions |
| Cartalax | Khavinson short peptide bioregulator | 3 residues | ~333 Da | One small unregistered human study, n=29 | Cartalax version only |
| GHK-Cu | Copper-bound tripeptide, isolated 1973 | 3 residues | ~340 Da plus copper | Controlled human studies, almost entirely topical | Four-peptide version only |
Read that table as a map of where the evidence actually sits, not as a ranking. The compound with the most human trial data behind it (thymosin beta-4) has that data for a formulation and a route nobody in this market is using, and the compound with the least (Cartalax) is the one whose identity is most often misprinted.
BPC-157
BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), molecular weight approximately 1419 Da. "BPC" stands for Body Protection Compound, a series of peptide fractions isolated and screened by Predrag Sikiric and colleagues at the University of Zagreb, first published in 1993. It is described as derived from a protein found in human gastric juice, but it does not occur naturally as a standalone 15-residue compound.
What the pharmacokinetics show: after single intravenous administration in rats the average elimination half-life was 15.2 minutes, and in beagle dogs 5.27 minutes. Elimination half-life was under 30 minutes in both species at every dose tested. Peak time after intramuscular administration was 3 minutes. The compound shows linear pharmacokinetics across the tested range. Published human pharmacokinetic analysis found plasma concentrations returned to baseline within 24 hours.
What the evidence base looks like: extensive in rodents, extremely thin in humans. A 2025 narrative review of BPC-157 for musculoskeletal healing identified only three published human studies: a 2021 report in which 14 of 16 knee-pain patients improved, a 2024 report of 12 interstitial cystitis patients, and a 2025 report of two healthy volunteers tolerating intravenous infusion. The review's own conclusion is that BPC-157 "should be considered investigational, and its use approached with caution."
A structural criticism of the literature matters more than any single study. Polish reviewers have noted that the overwhelming majority of indexed BPC-157 records trace to Sikiric's group, which has published over 150 papers on the compound, and that experiments routinely test only a single dose. A 2025 review from that group referred to a clinical trial finding the compound safe and well tolerated in humans without citing a published paper or releasing data. A trial registered on clinicaltrials.gov in 2015 testing oral BPC-157 was withdrawn before outside review, with no results published.
Salt form is a detail most blend listings omit. Two forms circulate: acetate, which dominates the published literature, and arginate, a basic amino acid salt that is substantially more stable under acidic conditions. A blend certificate that does not name the salt form has not fully described what is in the vial.
TB-500
TB-500 is where the labelling gets genuinely ambiguous, and the ambiguity is rarely disclosed.
Thymosin beta-4 is a naturally occurring 43-amino-acid protein whose primary characterised activity is sequestering monomeric G-actin, controlling how much actin is available to polymerise into filaments. TB-500, as originally characterised in the anti-doping literature, is not that protein. It is the N-terminally acetylated seven-residue fragment Ac-LKKTETQ, corresponding to residues 17 to 23 of thymosin beta-4, which spans the actin-binding domain.
In practice, material sold as TB-500 is sometimes the full-length 43-residue protein and sometimes the 7-residue fragment. Those are not interchangeable: they differ by roughly a factor of six in molecular weight, which means a stated milligram figure corresponds to completely different molar quantities depending on which one is in the vial. Aggregator descriptions of the Deadpool blend openly note that TB-500 is "sold as either full-length thymosin beta-4 or its 17-23 fragment." Some vendors sidestep the question by writing "TB4" on the label, which resolves nothing.
What the human evidence shows: full-length thymosin beta-4 has been through real clinical trials, which is more than can be said for most peptides in this category, and the results are mixed. RGN-259, a 0.1% thymosin beta-4 ophthalmic solution, showed complete healing in 6 of 10 treated subjects versus 1 of 8 on placebo in a Phase 3 neurotrophic keratopathy trial, with no significant adverse effects. A later European Phase 3 trial (SEER-3) missed its primary endpoint, attributed to a stronger than expected placebo response. The injectable systemic formulation, RGN-352, has been described as Phase 2-ready for years. None of that evidence is about the 7-residue fragment, and none of it is about subcutaneous research use.
KPV
KPV is the tripeptide Lys-Pro-Val, molecular weight approximately 342 Da, corresponding to residues 11 to 13 of alpha-melanocyte-stimulating hormone. It is the C-terminal fragment of alpha-MSH, and it is the best-characterised anti-inflammatory component in any Deadpool formulation.
The mechanism is unusually well described for a peptide in this market. Nanomolar concentrations of KPV inhibit activation of NF-kappaB and MAP kinase inflammatory signalling and reduce pro-inflammatory cytokine secretion, and uptake into intestinal epithelial and immune cells is mediated by the PepT1 transporter. Published work found KPV exerts a stronger anti-inflammatory effect than alpha-MSH itself, and that its effect is mechanistically distinct from the core MSH peptides: it is unlikely to act through melanocortin receptors and more likely to work through inhibition of interleukin-1 beta functions.
The animal model work is specific rather than vague. Oral KPV reduced the incidence of colitis induced by dextran sodium sulfate and by trinitrobenzene sulfonic acid in mice. Hyaluronic-acid-functionalised nanoparticles carrying KPV reduced lipopolysaccharide-driven inflammatory responses in intestinal cells in a dose-dependent way and protected treated mice against inflammatory and histologic parameters of colitis.
The limitation is the familiar one: this is cell-culture, rodent and formulation work. There is no large randomised human trial establishing KPV as a proven therapy for anything.
Cartalax, and the Sequence Problem
Cartalax is a Khavinson-series short peptide bioregulator, developed at the St. Petersburg Institute of Bioregulation and Gerontology and associated with cartilage and connective tissue. It sits in the same family as Epitalon, Vilon, Vesugen and Pinealon: very short synthetic sequences proposed to act as tissue-specific regulatory signals.
Here is the problem. Cartalax is the tripeptide Ala-Glu-Asp, abbreviated AED, molecular formula C12H19N3O8, molecular weight approximately 333 Da. A large number of vendor listings, including listings for the Deadpool blend specifically, describe Cartalax as Ala-Glu-Asp-Leu (AEDL). AEDL is Bronchogen, the bronchial and pulmonary peptide in the same Khavinson series.
The family structure makes the error easy to see once you know it. AED is the tripeptide core. The tetrapeptides extend it with a fourth residue that carries the tissue specificity: Gly for the pineal peptide Epitalon (AEDG), Leu for the bronchial peptide Bronchogen (AEDL), Arg for the cardiac peptide Cardiogen (AEDR). A listing that prints "Cartalax (Ala-Glu-Asp-Leu)" has named the cartilage peptide and described the lung peptide.
One residue is the whole difference. The three-bead chain is Cartalax (AED). Add a fourth residue and you have a different molecule with a different mass, and which residue you add decides which one: Gly gives Epitalon, Leu gives Bronchogen, Arg gives Cardiogen.
| Khavinson peptide | Sequence | Length | Associated tissue |
|---|---|---|---|
| Cartalax | Ala-Glu-Asp (AED) | 3 | Cartilage and connective tissue |
| Epitalon | Ala-Glu-Asp-Gly (AEDG) | 4 | Pineal |
| Bronchogen | Ala-Glu-Asp-Leu (AEDL) | 4 | Bronchial and pulmonary |
| Cardiogen | Ala-Glu-Asp-Arg (AEDR) | 4 | Cardiac |
This is not a pedantic distinction. It is the difference between two different molecules with different masses, and it determines what a mass spectrometry identity check should be looking for. If a certificate confirms a mass consistent with AEDL while the label says Cartalax, the certificate and the label do not agree, and only one of them can be right.
The evidence base for Cartalax itself is weak and largely unreplicated outside the group that created it. The proposed mechanism is modulation of chondrocyte gene expression (SOX9, aggrecan, type II collagen, COMP) and of ageing markers (SIRT1, SIRT6, Ki-67, p53). The human data amounts to one small unregistered study of 29 knee osteoarthritis patients reporting pain and mobility improvements in the range of 54.5% to 62.7%, published without p-values, without an adverse event table, and without radiographic confirmation. That study used intramuscular administration, while commercial Khavinson products are generally oral or sublingual. Independent evidence graders place it at the bottom of the scale, and it holds no FDA or EMA approval; in Russia it is marketed as a dietary supplement.
GHK-Cu
GHK-Cu appears only in the four-peptide version, where it is usually the dominant component by mass: 50mg of an 80mg vial, a 5:1:1:1 ratio against the other three.
GHK is the tripeptide glycyl-L-histidyl-L-lysine, molecular weight approximately 340 Da, isolated by Loren Pickart in the early 1970s after observing that plasma from younger adults revived cultured liver cells. Plasma levels decline with age. GHK-Cu is the complex of that tripeptide with copper(II).
The mechanism literature is genuinely substantial. GHK-Cu stimulates both synthesis and breakdown of dermal matrix components, upregulating MMP-2 to clear damaged collagen while promoting new matrix synthesis. That coordinated remodelling, rather than simple stimulation of growth, is what distinguishes it from a growth factor. Pickart's 2018 gene-data review reported Broad Institute data showing GHK altering a large fraction of human genes at a 50% threshold, and cited a one-month thigh biopsy study in which increased collagen production occurred in 70% of GHK-Cu treated women versus 50% of controls.
The important caveat is route. Controlled human studies of GHK-Cu have focused almost exclusively on topical application for skin and, to a lesser extent, wound healing and hair. The injectable use that puts it in a research blend is running ahead of that evidence. Dermatologists interviewed in September 2026 coverage of the trend named two specific concerns for injected copper peptides: overloading the system with copper, and triggering an immune reaction. One was quoted saying they would not sleep well "until the human studies are actually done." Copper is the part of the molecule that makes this different from the other three components, because copper has a dose-dependent toxicity profile that a peptide backbone does not.
What the Evidence Says About the Blend as a Blend
Nothing. That is the finding, and it is worth stating plainly rather than burying.
No high-quality human study evaluates any Deadpool or KLOW formulation as a combined product. Vendor and clinic pages that describe the components as "synergistic" are making an inference from four separate single-compound literatures, three of which are predominantly preclinical and one of which is predominantly topical. Even the most detailed guide to the four-peptide version concedes in its own text that no such studies were identified and that synergy claims remain theoretical.
Combination pharmacology is not additive by default. Two compounds that both modulate inflammatory signalling may be redundant rather than complementary, and one may alter the clearance or stability of the other. Establishing that a combination does something its components do not requires studying the combination, and that study does not exist for any version of this blend.
Why a Blend Is Harder to Verify Than Its Parts
This is the part that matters most for procurement, and it is covered at greater length in our article on the analytical trade-offs of peptide blends.
Above, a single peptide: one peak is the product and everything else is an impurity, so a purity percentage means something. Below, a four-peptide blend: no peak is the product, all four are, and the same percentage has quietly stopped describing the vial.
Purity of what? For a single peptide, a purity figure has an unambiguous referent: how much of the detectable material is the compound on the label. Put three or four peptides in one vial and the arithmetic stops applying. The largest peak is not the product, it is one component of the product, and the other named peaks are not impurities. A single purity percentage on a blend certificate is either measuring one component and calling it the vial, summing the named component areas in a way that would conceal a missing component, or reporting certificates for the input materials rather than for the vial that was filled.
Co-elution. If two components are not chromatographically resolved from each other, one peak integrates as one component and the ratio between them is simply not present in the data. A method that resolves BPC-157 from TB-500 will not necessarily resolve a 342 Da tripeptide from a 333 Da tripeptide. A blend certificate should state that the method separates the components, not merely that a method was run.
Content uniformity. Lyophilisation of a multi-component solution does not guarantee homogeneous distribution through the cake. Components adsorb to fill lines and vial surfaces at different rates and dissolve at different rates on reconstitution. A stated "5mg plus 5mg plus 10mg" is a fill target, not a measurement of what ended up in the vial you received.
Differential stability. Peptides degrade on sequence-specific timescales and are sensitive to different pH and temperature conditions. A single storage condition for a four-component vial is a compromise, and the component with the shortest shelf life sets the real expiry for the product even though the label does not say so.
A blend certificate that is actually worth reading answers seven questions: identity confirmed for each component separately, purity for each component separately, content assay for each against its own reference standard, the ratio and how it was established, the parent lot numbers of the input materials, and evidence that the analytical method resolves the components from one another. LC-MS can confirm identity against each peptide's expected mass, which is exactly the check that would catch an AEDL peptide sold as Cartalax. A certificate that answers only identity and purity at the vial level has described a raw material, not a mixture.
The Fixed-Ratio Trade
A blend removes a degree of freedom. Once components share a vial, they cannot be varied independently, and any change to one is a change to all of them in a fixed proportion.
That matters more here than in a two-component vial because the components are not pharmacokinetically similar. BPC-157 has an elimination half-life under 30 minutes in every species tested. Full-length thymosin beta-4 and the LKKTETQ fragment have different clearance profiles again. GHK-Cu at 50mg in an 80mg vial dominates the mass but is the component with the least human injectable evidence behind it. Any experimental design that would treat these as independent variables is impossible in a single vial, and a result obtained with one vendor's ratio does not transfer to another vendor's ratio.
It also makes replication harder. If the internal composition of the vial cannot be verified to the milligram, conditions cannot be recreated and results cannot be compared against other work. That is a reasonable trade for convenience in some contexts and a fatal one in others, but it should be a decision rather than a surprise.
Market Quality Reality
The blend question sits on top of a market-wide sourcing question.
A 2023 survey of peptide products purchased online found that 23% failed label-claim verification, through absence of the stated active peptide, presence of unlabelled compounds, or a quantitative mismatch between labelled and actual content. Independent testing aggregating over 6,100 samples across 185 vendors reported that close to 40% of vendors fail to meet their stated purity. Quantity divergence of up to 46% from the advertised figure has been documented, meaning a vial labelled 10mg holding closer to 5.4mg.
Anti-doping authorities have made the same point in blunter language. The chief science officer of the US Anti-Doping Agency, speaking about grey-market BPC-157, put it as: "You don't even know what you're buying inside that bottle."
Every one of those failure modes is harder to detect in a blend, because the analytical baseline against which you would detect it is exactly the thing a blend certificate struggles to establish. Our standing position on this is on the certificates of analysis page and the quality page, and the independent laboratories that will run this kind of analysis are listed in the peptide testing labs directory.
Regulatory Status of Every Component
None of these compounds is an approved drug in the United States or Canada. This is not a grey area that varies by component.
| Compound | FDA 503A compounding | Prohibited in sport | Named in Health Canada advisory |
|---|---|---|---|
| BPC-157 | Category 2 since September 2023 | Yes, S0 non-approved substances, added to the 2022 WADA List, prohibited at all times | Yes |
| TB-500 / thymosin beta-4 | Category 2 since September 2023 (fragment LKKTETQ named) | Yes, thymosin beta-4 and its derivatives under S2 growth factors, prohibited at all times | Yes |
| KPV | Category 2 since September 2023 | Not specifically named | Yes |
| GHK-Cu | Not approved as a drug; topical cosmetic use is a separate regulatory lane | Not specifically named | Yes |
| Cartalax | No approval; marketed as a dietary supplement in Russia | Not specifically named | Not named |
Category 2 on the FDA's interim 503A bulks list means the agency has identified significant safety risks and that compounding pharmacies should not compound the substance. BPC-157, TB-500, KPV and MOTS-C are scheduled for Pharmacy Compounding Advisory Committee review in July 2026, which could move them to Category 1, and that review is the thing to watch rather than any individual vendor's claims about status.
Health Canada's advisory of 9 April 2026 names BPC-157, CJC-1295, DSIP, Epitalon, GHK-Cu, HCG, Ipamorelin, KPV, Melanotan I and II, MOTS-C, NAD+, SS-31, TB-500 and retatrutide. Four of the five compounds that appear in some version of the Deadpool blend are on that list. The advisory states explicitly that a "research use only" label "does not make these products legal or exempt from regulatory requirements," and that Health Canada has seized unauthorised injectable peptide drugs and works with border authorities to stop unauthorised shipments. The risks it names are hormonal imbalance, mood swings, blood sugar imbalance, liver or kidney damage, blood clots, tumour growth, infection, allergic reaction, incorrect dosing, undisclosed ingredients, and contamination with solvents, heavy metals, bacteria and fungi.
For anyone under anti-doping jurisdiction, note that no therapeutic use exemption is available for BPC-157, because a TUE requires an approved therapeutic agent and there is none. Sanctions have been issued: a Canadian athlete received a four-year period of ineligibility for BPC-157 and TB-500.
How to Evaluate a Deadpool Blend Listing
If you are assessing one of these vials for a research procurement decision, these are the questions that actually separate listings:
- Which formulation is it? Three components or four, and which three. Do not assume from the name.
- What is the split, and does it sum to the stated total? A 20mg vial at 5/5/10 and a 30mg vial at 10/10/10 are different products at different per-milligram costs.
- What sequence does the listing give for Cartalax? AED is correct. AEDL is Bronchogen. A listing that gets this wrong has not verified its own label copy, which is informative about everything else on the page.
- What is TB-500 here, the 43-residue protein or the 7-residue fragment? If the listing does not say, the milligram figure on the label is not interpretable in molar terms.
- What salt form is the BPC-157? Acetate and arginate behave differently under acidic conditions.
- Does the certificate report each component separately? Identity, purity and content assay per component, against separate reference standards, with the ratio stated and the method shown to resolve the components.
- Is the certificate for this vial's lot, or for the input materials? Input certificates describe what went into the process, not what came out.
- Is there a lab verification path you can follow yourself? A report identifier you can check on the issuing laboratory's own site is worth more than a PDF, because a PDF is the most forgeable document in this market.
Frequently Asked Questions
Is the Deadpool blend the same as KLOW?
Sometimes. The four-peptide version (BPC-157, TB-500, KPV, GHK-Cu) is sold under both names. The three-peptide versions are not KLOW. Treat the two names as overlapping rather than equivalent.
Is it the same as the Wolverine stack?
No. The Wolverine stack is BPC-157 plus TB-500 only. Every Deadpool version is that pair plus at least one more compound. The naming is deliberate lineage.
Which version is "the real one"?
Neither. There is no standard-setting body for peptide blend nicknames, no originator formulation, and no reason to expect convergence. The Cartalax version and the KPV version are both widely sold, by different vendors, with no relationship between them beyond two shared components.
Why does Cartalax appear in a tissue-repair blend at all?
Its proposed activity is cartilage and connective tissue specific, which is adjacent to but distinct from the soft-tissue repair rationale for BPC-157 and TB-500. Whether that adjacency produces anything in combination is untested.
Does a higher total milligram figure mean a better vial?
No. The 80mg four-peptide version is 50mg GHK-Cu, so its headline number is dominated by one component. Compare per-component milligrams, not vial totals.
Are these compounds legal to buy?
The compounds are sold widely as research materials. That is not the same as being legal to administer. Health Canada's position is that unauthorised injectable peptides are illegal in Canada and that a research-use-only label changes nothing about that. The FDA has not approved any of them, and four sit in 503A Category 2.
Does Volta sell a Deadpool blend?
No. Our catalogue lists BPC-157, TB-500, KPV and GHK-Cu as single-compound vials, and one two-peptide blend, BPC-157 with TB-500. We do not stock Cartalax. Single vials are the more defensible purchase for anyone who needs the ratio to be a variable rather than a constant, and they are the only way to get a certificate whose purity figure means what a purity figure normally means.
Sources
Primary literature and regulatory positions consulted for this article:
- Sikiric et al., original BPC-157 characterisation, University of Zagreb, 1993 onward
- Pharmacokinetics, distribution, metabolism and excretion of body-protective compound 157 in rats and dogs, Frontiers in Pharmacology, 2022
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing, 2025
- BPC-157 as an Investigational Peptide Therapeutic, Pharmaceutics, 2026
- Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, 2012
- RGN-259 Phase 3 neurotrophic keratopathy trial results, 2023, and the SEER-3 European Phase 3 outcome
- Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides, 2003
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation, Gastroenterology, 2008
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles, Molecular Therapy, 2016
- Khavinson short peptide bioregulator series, St. Petersburg Institute of Bioregulation and Gerontology
- Pickart, Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data, 2018
- FDA interim 503A bulk drug substances list, Category 2 additions of September 2023
- WADA Prohibited List, S0 and S2, 2022 onward, and USADA athlete advisories
- Health Canada advisory on unauthorised injectable peptide drugs, 9 April 2026
- STAT News, BPC-157: the peptide with big claims and scant evidence, February 2026
- NPR, The copper peptide trend has gone from creams to injections, September 2026
This article is written for laboratory and in-vitro research procurement. Nothing in it is medical advice, and no component discussed here is approved for human use in Canada or the United States.
